Data from the following clinical trials are discussed:

3721: Characterization of Bruton tyrosine kinase inhibitor (BTKi)-related adverse events in a head-to-head trial acalabrutinib versus ibrutinib in previously chronic lymphocytic leukemia (CLL)

68: First-line treatment with ibrutinib (Ibr) plus venetoclax (Ven) for chronic lymphocytic leukemia (CLL): 2-year post-randomization disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the phase 2 Captivate study

396: SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

67: Zanubrutinib in combination with venetoclax for patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): early results from arm D of the SEQUOIA (BGB-311-304) trial

1410: Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (Pts) with relapsed/refractory B-cell malignancies

395: A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): a minimal residual disease (MRD)-driven, time-limited approach

391: Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study

Supported in part by Takeda Oncology. Content developed independently by Onclive®.

Videos

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia. 

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape 

310: Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 tyrosine kinase inhibitors: update after 48 weeks

307: Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline 

 level and baseline mutation status in the Optic trial

Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.

ASH 2021: Key Data in Chronic Myeloid Leukemia 

1233: Updated results from a phase I study of hyper-CVAD with sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia

1231: Superior overall survival with blinatumomab versus chemotherapy as pre-transplant consolidation treatment in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL): longer follow-up (FU) of a phase 3 randomized controlled trial (RCT)

4028: Successful outpatient administration of blinatumomab infusion in pediatric patients with acute lymphoblastic leukemia

516: Isatuximab in combination with chemotherapy in pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): interim analysis

428: Real-world outcomes for pediatric and young adult patients with relapsed refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting. 

Elias J. Jabbour, MD, MD Anderson

Articles

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

ASH 2021: Key Data in Chronic Myeloid Leukemia

ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia